Protein oxidation in metabolic syndrome

Clinical and Investigative Medicine

Volumn 36, Issue 1, 2013, Pages

  Hopps, Eugenia ^a   Caimi, Gregorio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; PROTEIN CARBONYLATION; REVIEW;

ANIMALS; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; METABOLIC SYNDROME X; OXIDATIVE STRESS; PROTEIN CARBONYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874958748     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL. Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol 2011; 48 (2): 157-165
2. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 2012; 49 (2): 89-95
3. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 2010; 20(1):72-77
4. Demircan N, Gurel A, Armuctu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malonildialdehyde and total antioxidant status in patients with metabolic syndrome. Med Sci Monit 2008; 14:97-101
5. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 2005; 289:228-236
6. Sun YX, Hu SJ, Zhang XH, Sun J, Zhu CH, Zhang ZJ. Plasma levels of vWF and NO in patients with mwtabolic syndrome and their relationship with metabolic disorders. Zhejiang Da Xue Xue Bao Yi Xue Ban 2006; 35:315-318
7. Kalousova M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005; 579: 37-46
8. Witko-Sarsat V, Gausson V, Nguyen A-T, Touam M, Drüeke T, Santangelo F, Descamps-Latscha B. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91
9. Li ZH, Liu SX, Hou FF, Wang YQ. Effect of advanced oxidation protein products on nitric oxide production in mouse peritoneal macrophages. Nan Fang Yi Ke Da Xue Xue Bao 2006; 26(5):558-60
10. Yuan F, Liu SX, Tian JW. Advanced oxidation protein products induce reactive oxygen species production in endothelial cells. Di Yi Jun Yi Da Xue Xue Bao 2004; 24(12):1350-2
11. Dalle Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2008; 524:601-623
12. Chouchani ET, James AM, Fearnley IM, Lilley KS, Murphy MP. Proteomic approaches to the characterization of protein thiol modification. Curr Opin Chem Biol 2011; 15(1):120-8
13. Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I. SGlutathionylation: from redox regulation of protein functions to human diseases. J Cell Mol Med 2004; 8:201-212
14. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction and disease progression. J Cell Mol Med 2006; 2:389-406
15. Sayre LM, Lin D, Yuan Q, Zhu X, Tang X. Protein adducts generated from products of lipid oxidation: focus on HNE and ONE. Drug Metab Rev 2006; 38:651-675
16. Sebekova K, Boor P, Valachovicova M, Blazicek P, Parrak V, Babinska K, et al. Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Mol Nutr Food Res 2006; 50:858-868
17. Meaney E, Vela A, Samaniego V, Meaney A, Asbún J, Zempoalteca JC, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008; 35(8):895-903
18. Krzystek-Korpacka M, Patryn E, Boehm D, Berdowska I, Zielinski B, Noczynska A. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 2008; 41:943-949
19. Frohnert BI, Sinaiko AR, Serrot FJ, Foncea RE, Moran A, Ikramuddin S, et al. Increased adipose protein carbonylation in human obesity. Obesity 2011; 19(9):1735-1741
20. Koçak H, Oner-Iyidogan Y, Gürdöl F, Oner P, Süzme R, Esin D, et al. Advanced oxidation protein products in obese women: its relation to insulin resistance and resistin. Clin Exp Med 2007; 7(4):173-178
21. Zhou QG, Zhou M, Lou AJ, Xie D, Hou FF. Advanced Oxidation Protein Products Induce Inflammatory Response and Insulin Resistance in Cultured Adipocytes via Induction of Endoplasmic Reticulum Stress. Cell Physiol Biochem 2010; 26:775-786
22. Atabek ME, Keskin M, Yazici C, Kendirci M, Hatipoglu N, Koklu E, et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr 2006; 165 (11):753-756
23. Uzun H, Konukoglu D, Gelisgen R, Zengin K, Taskin M. Plasma protein carbonyl and thiol stress before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg 2007; 17(10):1367-1373
24. Sledzinski T, Goyke E, Smolenski RT, Sledzinski Z, Swierczynski J. Decrease in serum protein carbonyl groups concentration and maintained hyperhomocysteinemia in patients undergoing bariatric surgery. Obes Surg 2009; 19(3):321-326
25. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001; 86(1):355-362
26. Codoñer-Franch P, López-Jaén AB, De La Mano-Hernández A, Sentandreu E, Simó-Jordá R, Valls-Bellés V. Oxidative markers in children with severe obesity following low-calorie diets supplemented with mandarin juice. Acta Paediatr 2010; 99(12):1841-1846
27. Baynes JB, Thorpe SR. Role of Oxidative Stress in Diabetic Complications: A New Perspective on an Old Paradigm. Diabetes 1999; 48:1-9
28. Turk Z. Glycotoxines, Carbonyl Stress and Relevance to Diabetes and Its Complications. Physiol Res 2010; 59: 147-156
29. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99(2):224-229
30. Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger Ebselen. J Am Soc Nephrol 2004; 15:2391-403
31. Kielstein JT, Tsao PS. From Zanius to ADMA: ADMA a new "adipocytokine" and its potential role in metabolic syndrome. J Nephrol 2007; 20:515-517
32. Ahmed N, Baraei-jadidi R, Howell SH, Thornalley PJ, Beisswenger PJ. Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes. Diabetes Care 2005; 28:2465-2471
33. Telci A, Cakatay U, Kayali R, Erdogan C, Orhan Y, Sivas A, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 2000; 32: 40-43
34. Adaikalakoteswari A, Balasubramanyam M, Rema M, Mohan V. Differential gene expression of NADPH oxidase (p22phox) and hemoxygenase-1 in patients with type 2 diabetes and microangiopathy. Diabetic Med 2006; 23: 666-674
35. Odetti P, Garibaldi S, Noberasco G, Aragno I, Valentini S, Traverso N, et al. Levels of carbonyl groups in plasma proteins of type 2 diabetes mellitus subjects. Acta Diabetol 1999; 36: 179-183
36. Sarkar P, Kar K, Mondal MC, Chakraborty I, Kar M. Elevated Level of Carbonyl Compounds Correlates with Insulin Resistance in Type 2 Diabetes. Ann Acad Med Singapore 2010; 39:909-912
37. Sathiyapriya V, Selvaraj N, Bobby Z, Agrawal A. Perturbation of erythrocyte antioxidant barrier, lipid peroxidation and protein carbonylation in non-diabetic first degree relatives of patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 78: 171-175
38. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005; 31(6):551-557
39. Kalousova M, Krha J, Zima T. Advanced Glycation End-Products and Advanced Oxidation Protein Products in Patients with Diabetes Mellitus. Physiol Res 2002; 51: 597-604
40. Tabak O, Gelisgen R, Erman H, Erdenen F, Muderrisoglu C, Aral H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 2011; 34(3):E163-171
41. Piwowar A. Advanced oxidation protein products. Part II. The significance of oxidation protein products in the pathomechanism of diabetes and its complications. Pol Merkur Lekarski 2010; 28(165):227-230
42. Piwowar A, Knapik-Kordecka M, Warwas M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br J Biomed Sci 2009; 66(4):194-199
43. Gelisgen R, Genc H, Kayali H, Oncul M, Benian A, Guralp O, et al. Protein oxidation markers in women with and without gestational diabetes mellitus: A possible relation with paraoxonase activity. Diab Res Clin Pract 2011; doi:10.1016/j.diabres.2011.08.001
44. Baskol G, Gumus K, Oner A, Arda H, Karakucuk S. The role of advanced oxidation protein products and total thiols in diabetic retinopathy. Eur J Ophthalmol 2008; 18(5):792-798
45. Margetis PI, Antonelou MH, Petropoulos IK, Margaritis LH, Papassideri IS. Increased protein carbonylation of red blood cell membrane in diabetic retinopathy. Exp Mol Pathol 2009; 87: 76- 82
46. Konukoglu D, Kemerli GD, Sabuncu T, Hatemi HH. Protein carbonyl content in erythrocyte membranes in type 2 diabetic patients. Horm Metab Res 2002; 34: 367-370
47. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophtalmol 2008; 92: 548-551
48. Rattan R, Nayak D. High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: a preliminary communication. Int J Low Extrem Wounds 2008; 7(4):198-203
49. Ahmed N, Baraei-jadidi R, Howell SH, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005; 48: 1590-1603
50. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998; 21: 1736-1742
51. Cumaoglu A, Cevik C, Rackova L, Ari N, Karasu C. Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin-diabetic rats: role of oxidative/nitrosative stress. Biofactors 2007; 30(3):171-178
52. Zhou LL, Hou FF, Wang GB, Yang F, Xie D, Wang YP, et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 2009; 76(11):1148-1160
53. Shao CH, Rozanski GJ, Nagai R, Stockdale FE, Patel KP, Wang M, et al. Carbonylation of myosin heavy chains in rat heart during diabetes. Biochem Pharmacol 2010; 80: 205-217
54. Chen K, Xie F, Liu S, Li G, Chen Y, Shi W, et al. Plasma reactive carbonyl species: Potential risk factor for hypertension. Free Radic Res 2011; 45(5):568-574
55. Inagi R, Miyata T. Oxidative protein damage with carbohydrates and lipids in uremia: 'Carbonyl stress'. Blood Purif 1999; 17: 95- 98
56. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578
57. Mimic-Oka J, Simic T, Pljesa M, Stupar N, Turkovic S. Oxidative modifications of plasma proteins in different stages of chronic renal failure. Facta Universitatis 2001; 8: 1-5
58. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 2006; 20(2):149-155
59. Nandeesha H, Sathiyapriya V, Bobby Z, Pavithran P, Agrawal A, Selvaraj N. Altered oxidant-antioxidant status in non-obese men with moderate essential hypertension. Indian J Med Sci 2007; 61(6):326-331
60. Caner M, Karter Y, Uzun H, Curgunlu A, Vehid S, Balci H, et al. Oxidative stress in human in sustained and white coat hypertension. Int J Clin Pract 2006; 60(12):1565-1571
61. Caimi G, Mulè G, Hopps E, Carollo C, Lo Presti R. Protein oxidation in mild essential hypertension. Clin Hemorheol Microcirc 2012; 50: 193-195
62. Kedziora-Kornatowska K, Czuczejko J, Szewczyk-Golec K, Motyl J, Szadujkis-Szadurski L, Kornatowski T, et al. Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension. Clin Exp Pharmacol Physiol 2006; 33(8):751-756
63. Ren J. Influence of gender on oxidative stress, lipid peroxidation, protein damage and apoptosis in hearts and brains from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2007; 34(5-6):432-438
64. Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, et al. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 2004; 6(1):89-97
65. Klafke JZ, da Silva MA, Facchini Panigas T, Belli KC, de Oliveira MF, Barichello MM, et al. Effects of Campomanesia xanthocarpa on biochemical, hematological and oxidative stress parameters in hypercholesterolemic patients. J Ethnopharmacol 2010; 127: 299-305
66. Duarte MM, Moresco RN, Duarte T, Santi A, Bagatini MD, Da Cruz IB, et al. Oxidative stress in hypercholesterolemia and its association with Ala16Val superoxide dismutase gene polymorphism. Clin Biochem 2010; 43(13-14):1118-1123
67. Pirinccioglu AG, Gökalp D, Pirinccioglu M, Kizil G, Kizil M. Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia. Clin Biochem 2010; 43(15):1220-1224
68. Matteucci E, Biasci E, Giampietro O. Advanced oxidation protein products in plasma: stability during storage and correlation with other clinical characteristics. Acta Diabetol 2001; 38(4):187-189
69. Manfredini V, Biancini GB, Vanzin CS, Dal Vesco AM, Wayhs CA, Peralba Mdo C, et al. Apolipoprotein, C-reactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin. Arch Med Res 2010; 41(2):104-109
70. Maeda K, Yasunari K, Sato EF, Inoue M. Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Atherosclerosis 2005; 181:87-92
71. Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-γ and aortic stiffness in hypercolesterolemia. Am J Physiol Circ Physiol 2006; 291:2522-2532
72. Kumar SA, Sudhahar V, Varalakshmi P. Oxidative renal injury and lipoprotein oxidation in hypercholesterolemic atherogenesis: Role of eicosapentaenoate-lipoate (EPA-LA) derivative. Prostaglandins Leukot Essent Fatty Acids 2006; 75(1):25-31
73. Aydin S, Uzun H, Sozer V, Altug T. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacol Res 2009; 59(4):242-247
74. Hill MF. Emerging role for antioxidant therapy in protetion against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants. Curr Cardiol Rev 2008; 4:259-268
75. Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Pokkala-Sarathao E et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000; 248(5): 377-386
76. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-925
77. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002; 25(11): 1919-1927
78. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the vitamin E atherosclerosis prevention study (VEAPS). Circulation 2002; 106(12): 1453-1459
79. Lee IM, Cook NR, Graziano JM, Gordon D, Ridker PM, Manson JE et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the women's health study: a randomized controlled trial. JAMA 2005; 294(1): 56-65
80. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease. The women's antioxidant and cardiovascular study. Circulation 2009; 119: 2772-2780
81. Debreceni B, Debreceni L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther 2012; 30: 227-233
82. Matkovics A. Recent changes in concepts of antioxidant treatment. Orv Hetil 2006; 23: 747-752.